BioCentury | Jul 10, 2020
Politics, Policy & Law

Pharmas to invest $1 billion in biotechs to fight AMR as bridge to market reforms

Twenty-three pharmas have banded together to create a $1 billion fund to provide bridges from Phase II to approval for biotechs trying to advance products that combat antimicrobial resistance. The AMR Action Fund will be...
BioCentury | Feb 11, 2020
Product Development

Feb. 10 Product Development Quick Takes: Priority Review for Gilead CAR T cell therapy; plus Zai, Aquestive, Biohaven, Oculis, Blue Water, GlycoMimetics, Fluidi

Gilead’s second CAR T under Priority Review  Gilead Sciences Inc. (NASDAQ:GILD) said FDA accepted and granted Priority Review to a BLA for KTE-X19 to treat adults with relapse or refractory mantle cell lymphoma. The anti-CD19...
BC Extra | Dec 21, 2019
Company News

Dec. 20 Company Quick Takes: Genmab partners with CureVac; plus pair of Biogen deals, Ionis, Akcea-Novartis, Paratek and J&J-Taris

CureVac, Genmab to develop RNA-encoded antibody  Genmab A/S (NASDAQ:GMAB; CSE:GMAB) and CureVac AG have partnered to discover an mRNA-encoded antibody candidate to treat cancer. Genmab will pay $10 million up front and invest €20 million...
BC Extra | Dec 11, 2019
Clinical News

Iterum antibiotic fails in Phase III for intra-abdominal infections, further driving down shares

Iterum became the latest anti-infective developer to suffer a blow in the market, losing more than a third of its value with a narrow miss on the primary endpoint in a pivotal trial. Still, the...
BC Extra | Sep 9, 2019
Company News

Management tracks: Coles to lead Cerevel; plus Genfit, Jubilant, Paratek, Mogrify, Dementia Discovery Fund and Ayala

Cerevel Therapeutics LLC (Boston, Mass.) hired Tony Coles as CEO. Coles is Cerevel’s executive chairman as well as the co-founder and executive chairman of neurodegeneration company Yumanity Therapeutics LLC (Cambridge, Mass.), where he was until...
BC Extra | Aug 23, 2019
Politics & Policy

Coalition forms to push changes in antimicrobial payment system

To ensure that companies are incentivized to develop new antibiotics, a coalition of industry leaders has launched Working to Fight AMR to raise public awareness of antimicrobial resistance and encourage grassroots action to push forward...
BC Extra | Aug 21, 2019
Company News

Management tracks: VenatoRx builds out development team; plus Arbutus, Cadent and Arsenal Capital

Versant Ventures-backed VenatoRx Pharmaceuticals Inc. (Malvern. Pa.) hired Jennifer Ellis as SVP, quality. She was head of quality assurance at Tracon Pharmaceuticals Inc. (NASDAQ:TCON). The infectious disease company also hired Paul McGovern as VP, medical...
BC Extra | Aug 16, 2019
Company News

Ahead of FDA decisions on one antibiotic, Nabriva plans resubmission of another

As it awaits FDA's decisions on twin NDAs for lefamulin, Nabriva said it plans to resubmit an NDA early next quarter for another one of its antibiotics following a complete response letter this year. Nabriva...
BC Extra | Jun 29, 2019
Company News

Management tracks: Carrick names Pearson CEO in U.S. push; plus AC Immune, Paratek and more

Cancer company Carrick Therapeutics Ltd. (Dublin, Ireland) hired Tim Pearson as CEO. He succeeds Elaine Sullivan, one of the company's founders, who will become executive entrepreneur and an adviser to the board. Pearson, who was...
BC Extra | Apr 16, 2019
Company News

Achaogen files for bankruptcy amid continued headwinds for antibiotic developers

Following regulatory headwinds and what it called very limited uptake of its sole marketed antibiotic, Achaogen filed for Chapter 11 bankruptcy late Monday. It is one of several antibiotic companies that have lost over half...
Items per page:
1 - 10 of 150
BioCentury | Jul 10, 2020
Politics, Policy & Law

Pharmas to invest $1 billion in biotechs to fight AMR as bridge to market reforms

Twenty-three pharmas have banded together to create a $1 billion fund to provide bridges from Phase II to approval for biotechs trying to advance products that combat antimicrobial resistance. The AMR Action Fund will be...
BioCentury | Feb 11, 2020
Product Development

Feb. 10 Product Development Quick Takes: Priority Review for Gilead CAR T cell therapy; plus Zai, Aquestive, Biohaven, Oculis, Blue Water, GlycoMimetics, Fluidi

Gilead’s second CAR T under Priority Review  Gilead Sciences Inc. (NASDAQ:GILD) said FDA accepted and granted Priority Review to a BLA for KTE-X19 to treat adults with relapse or refractory mantle cell lymphoma. The anti-CD19...
BC Extra | Dec 21, 2019
Company News

Dec. 20 Company Quick Takes: Genmab partners with CureVac; plus pair of Biogen deals, Ionis, Akcea-Novartis, Paratek and J&J-Taris

CureVac, Genmab to develop RNA-encoded antibody  Genmab A/S (NASDAQ:GMAB; CSE:GMAB) and CureVac AG have partnered to discover an mRNA-encoded antibody candidate to treat cancer. Genmab will pay $10 million up front and invest €20 million...
BC Extra | Dec 11, 2019
Clinical News

Iterum antibiotic fails in Phase III for intra-abdominal infections, further driving down shares

Iterum became the latest anti-infective developer to suffer a blow in the market, losing more than a third of its value with a narrow miss on the primary endpoint in a pivotal trial. Still, the...
BC Extra | Sep 9, 2019
Company News

Management tracks: Coles to lead Cerevel; plus Genfit, Jubilant, Paratek, Mogrify, Dementia Discovery Fund and Ayala

Cerevel Therapeutics LLC (Boston, Mass.) hired Tony Coles as CEO. Coles is Cerevel’s executive chairman as well as the co-founder and executive chairman of neurodegeneration company Yumanity Therapeutics LLC (Cambridge, Mass.), where he was until...
BC Extra | Aug 23, 2019
Politics & Policy

Coalition forms to push changes in antimicrobial payment system

To ensure that companies are incentivized to develop new antibiotics, a coalition of industry leaders has launched Working to Fight AMR to raise public awareness of antimicrobial resistance and encourage grassroots action to push forward...
BC Extra | Aug 21, 2019
Company News

Management tracks: VenatoRx builds out development team; plus Arbutus, Cadent and Arsenal Capital

Versant Ventures-backed VenatoRx Pharmaceuticals Inc. (Malvern. Pa.) hired Jennifer Ellis as SVP, quality. She was head of quality assurance at Tracon Pharmaceuticals Inc. (NASDAQ:TCON). The infectious disease company also hired Paul McGovern as VP, medical...
BC Extra | Aug 16, 2019
Company News

Ahead of FDA decisions on one antibiotic, Nabriva plans resubmission of another

As it awaits FDA's decisions on twin NDAs for lefamulin, Nabriva said it plans to resubmit an NDA early next quarter for another one of its antibiotics following a complete response letter this year. Nabriva...
BC Extra | Jun 29, 2019
Company News

Management tracks: Carrick names Pearson CEO in U.S. push; plus AC Immune, Paratek and more

Cancer company Carrick Therapeutics Ltd. (Dublin, Ireland) hired Tim Pearson as CEO. He succeeds Elaine Sullivan, one of the company's founders, who will become executive entrepreneur and an adviser to the board. Pearson, who was...
BC Extra | Apr 16, 2019
Company News

Achaogen files for bankruptcy amid continued headwinds for antibiotic developers

Following regulatory headwinds and what it called very limited uptake of its sole marketed antibiotic, Achaogen filed for Chapter 11 bankruptcy late Monday. It is one of several antibiotic companies that have lost over half...
Items per page:
1 - 10 of 150